



## **UK COVID-19 INQUIRY**

### **MODULE 4 - UPDATE TO CORE PARTICIPANTS**

**10 JANUARY 2024**

#### **Introduction**

1. The purpose of this update note is to provide Core Participants (CPs) with details about the key work being done to progress the Module 4 investigation. This is the third update note which has been prepared in relation to Module 4.
2. The Inquiry intends to issue a similar update note each month. It is likely that the topics covered in the note will change each month, but we will seek to provide a comprehensive update on the various areas of work that the Module 4 team is progressing.

#### **Confidentiality**

3. This update note contains information that is confidential. It is important that the update note, and the confidential information it contains, is held strictly subject to the terms of the Inquiry's confidentiality undertaking and only provided to those who have signed and returned an undertaking to the Inquiry. The confidentiality will continue to apply until such time that the information in the note is made public by the Inquiry.
4. Where a particular topic is not confidential and so is not subject to the undertaking, we have made this clear below.

#### **Hearing timetable (Confidential)**

5. As part of the Inquiry's continuous review of its timetable and work plan, the Inquiry has been looking closely at the plans for progressing its work in 2024. In doing so, it has also borne in mind the increasing pressure that it is putting on key material providers to respond to the demands of multiple Inquiry modules. In order to make sure that the module hearings in 2024 are effective and that the Inquiry's other work such as preparation of reports in Modules 1 and 2 is deliverable, the Chair has decided it is necessary to change the provisional listing for the substantive hearing in Module 4. It is hoped that rescheduling Module 4's hearings will enable material providers to prioritise Module 3 Rule 9 requests ensuring that Module 3 receives timely disclosure of evidence ahead of its hearings in Autumn this year.

6. We will provide further details on the rescheduled hearing dates as soon as we are able to.
7. As a result of these changes, there will be no preliminary hearing on 8 February 2024, as previously indicated. The second preliminary hearing in Module 4 will take place on 22 May 2024 at Dorland House in London.

#### **Out of time applications for Core Participant status (Not confidential)**

8. We have recently received applications for CP status in Module 4 from the Home Office, Deceased Management Advisory Group and the Independent Ambulance Group. These applications have been received considerably after the timelines provided by the Inquiry (the application window closed on 30 June 2023).
9. The Chair has considered these applications in accordance with the Core Participant Protocol (and in particular paragraph 10 in relation to late applications) and has granted Core Participant status to the Home Office. She has declined the applications of the Deceased Management Advisory Group and the Independent Ambulance Association. The Chair's determinations have been published on the Inquiry's website.

#### **Update on Rule 9 requests (Confidential)**

10. Over the last month, the Module 4 legal team has made a number of further requests for witness statements and associated documentation in accordance with Rule 9 of the Inquiry Rules 2006. Further information about these new requests is set out from paragraph 59 onwards in **Annex A**. To date, the Module 4 legal team has made 95 requests.
11. We are in the process of finalising a number of further Rule 9 requests and intend to issue these shortly. This includes requests for witness statements from:
  - i. Former Prime Minister, The Rt Hon Boris Johnson;
  - ii. Former Secretaries of State for Health and Social Care, The Rt Hon Matt Hancock MP and The Rt Hon Sajid Javid MP;
  - iii. Former Minister for Covid Vaccine Deployment, The Rt Hon Nadhim Zahawi MP and former Minister for Vaccines and Public Health, Maggie Throup MP.

#### **Disclosure (Confidential)**

12. Since the last update note, we have provided two further tranches of disclosure. Tranche 2 was provided to CPs on 8 December and comprised 930 Cabinet Office documents and 6 GO-Science documents. These were obtained in early Inquiry modules and

identified as necessary and relevant for disclosure in Module 4. Please note that some of these documents have been temporarily removed from the Module 4 Core Participant Workspace on Relativity, pending a further redaction review. The Inquiry expects to be in a position to re-release the documents on Relativity following consideration of any additional redaction requests received.

13. Tranche 3 was provided to CPs on 14 December and comprised 636 DHSC documents obtained in the Inquiry's earlier modules, but identified as necessary and relevant for disclosure in Module 4.
14. We anticipate making a further tranche of disclosure in the coming weeks, which will include documents provided by the Office of the Chief Medical Officer.
15. Module 4 CPs with section 40 funding should please note that time spent reviewing disclosure (either on Relativity or on the Inquiry's website when published) on other modules of this Inquiry will not be recoverable under the section 40 award for Module 4, unless the Inquiry has confirmed otherwise in advance.

#### **Instruction of expert witnesses (Confidential)**

16. As indicated in our October and November update notes, the Inquiry has now instructed experts to provide a report in the following areas:
  - i. Vaccine safety (Professor Dani Prieto-Alhambra, Professor of pharmaco- and device epidemiology);
  - ii. Vaccine delivery, to include vaccine coverage (Dr Ben Kasstan and Dr Tracey Chantler, Assistant Professors at the London School of Hygiene and Tropical Medicine); and
  - iii. Vaccine hesitancy (Dr Heidi Larson, Professor of Anthropology, Risk and Decision Science and Director of The Vaccine Confidence Project).
17. The Inquiry continues to liaise with potential experts in relation to the issue of the development and trials of new and repurposed therapeutics and will provide a further update on progress in due course.
18. The draft expert reports will be shared with CPs in due course so that they can comment on and/or provide additional key lines of questioning for consideration before each report is finalised.

#### **Every Story Matters (Not confidential)**

19. The Inquiry is holding the next set of Every Story Matters events across the next three months. Every Story Matters events are a way for people to share their experiences of the pandemic with the Inquiry in person. Some of these events will be targeted at

specific groups of people affected by the pandemic, while others are open to the general public. We will be working closely with specific CPs and other organisations, representing those most impacted by the pandemic, to promote the events. We will share more information about upcoming events on the [Every Story Matters events page](#) of our website, on our Facebook page and in future newsletters.

**Upcoming key dates (Not confidential)**

20. As indicated above, the Inquiry will hold a preliminary hearing on **22 May 2024**, at Dorland House in London. Future preliminary hearings will be 'hybrid' hearings and there will be an option for some CPs and/or legal representatives to join virtually if they wish. The hearings will also be live-streamed on YouTube, subject to a three minute delay. Further details will follow in the coming months.

**Module 4 Inquiry Legal Team**

**10 January 2024**

## **Annex A - update on Rule 9 requests (Confidential)**

### **1. The Cabinet Office**

A Rule 9 letter was issued on 4 October 2023. The Inquiry asked the Cabinet Office to address the following topics: Its structure, role, people and processes; key decisions actions and documents; preparedness to develop vaccines; roles and responsibilities; innovations introduced and lessons learned; prophylactics; preparedness to develop therapeutics; innovations introduced and lessons learned; eligibility and prioritisation; roll out; public messaging; vaccine hesitancy; vaccine as a condition of deployment; dis/misinformation; rapid response unit; inequalities and vaccine safety.

Current status: The Cabinet Office is due to provide its draft statement by 26 January 2024.

### **2. HM Treasury**

A Rule 9 letter was issued on 6 September 2023. The Inquiry asked HM Treasury to address the following topics: Its structure, role, people and processes; key decisions, actions and documents; development, procurement, manufacture and approval of Covid-19 vaccines; development of new therapeutics for Covid-19; vaccine delivery and the Vaccine Damage Payment Scheme.

Current status: HM Treasury provided its draft statement on 22 December 2023 and it is under consideration by the Inquiry

### **3. The Rt Hon Kemi Badenoch MP**

A Rule 9 letter was issued on 6 September 2023. The Inquiry asked The Rt Hon Kemi Badenoch MP to address the following topics: Her role, function and responsibilities as Minister for Equalities / Minister for Women and Equalities; equalities issues generally as they relate to the scope of Module 4; equality of vaccine coverage; existing inequalities and vaccine uptake; roll-out and access; vaccine hesitancy; public messaging; dis/misinformation; therapeutics and lesson learning related to vaccines and therapeutics.

Current status: Draft statement due by 23 February 2024.

### **4. The Scottish Government**

A Rule 9 letter was issued on 27 September 2023. The Inquiry asked the Scottish Government to address the following topics: An overview of the Scottish Government's role, functions and responsibilities in relation to the Module 4 topics; identification of key individuals, decisions, actions and documents; development of vaccines; procurement and manufacture of vaccines; approval of vaccines; development, trials and use of new therapeutics during the pandemic, in addition to the use of existing medications; vaccine delivery and roll-out procedures; eligibility and prioritisation decisions; public messaging;

barriers to vaccine uptake; vaccine safety issues; The Vaccine Damage Payment Scheme (“VDPS”) and lesson learning and planning for the future.

Current status: The Scottish Government provided its draft statement on 15 December 2023 and it is under consideration by the Inquiry.

**5. The Executive Office of Northern Ireland**

A Rule 9 letter was issued on 26 July 2023. The Inquiry asked the Executive Office of Northern Ireland to address the following topics: Its role in relation to vaccines and therapeutics; key decisions, actions and documents; development of vaccines; procurement and manufacture of vaccines; approval of vaccines; development, trials and use of new therapeutics during the pandemic, in addition to the use of existing medications; vaccine delivery and roll-out procedures; eligibility and prioritisation decisions; public messaging; barriers to vaccine uptake; vaccine safety issues; liaison with the Government of the Republic of Ireland; The Vaccine Damage Payment Scheme (“VDPS”); lesson learning and future planning.

Current status: The Executive Office of Northern Ireland’s draft statement was provided on 30 November 2023 and is under consideration by the Inquiry

**6. Department for Health & Social Care (DHSC)**

A Rule 9 request was issued on 20 July 2023 and a section 21 Notice issued on 16 October 2023 (and varied on 8 January 2024). The Inquiry asked the DHSC to address the following topics: DHSC’s role in relation to vaccines and therapeutics; key decisions, actions and documents; an explanation of the role, responsibilities and functions of key agencies, bodies and committees, development of vaccines; procurement and manufacture of vaccines; approval of vaccines; development, trials and use of new therapeutics during the pandemic, in addition to the use of existing medications; vaccine delivery and roll-out procedures; eligibility and prioritisation decisions; public messaging; barriers to vaccine uptake; vaccine safety issues; the Vaccine Damage Payment Scheme (“VDPS”); the VDPS and Covid 19 vaccines; VDPS eligibility and payment limits; the VDPS application process; reforms and lesson learning.

Current status: DHSC will be providing its draft statement in three parts. Part A is due on 19 January 2024, Part B is due on 26 January 2024 and Part C is due on 8 February 2024.

**7. Antonia Williams OBE (Director of Covid Vaccine Deployment, Department of Health and Social Care (DHSC))**

A Rule 9 request was issued on 1 August 2023. The Inquiry asked Antonia Williams OBE to address the following topics: An overview of her role and her role in respect of vaccines; vaccine delivery and roll out procedures; barriers to vaccine uptake; public messaging; mis/disinformation and lessons learned.

Current status: Antonia Williams is due to provide her draft statement on 31 January 2024.

**8. The Office of the Chief Medical Officer (OCMO)**

A Rule 9 request was issued on 29 June 2023. The Inquiry has asked OCMO to address the following topics: an overview of the role of the CMO and its role in respect to vaccines; vaccine delivery; new therapeutics and existing medications; public messaging relating to vaccines and learning lessons.

Current status: OCMO is due to provide its draft witness statement on 29 January 2024.

**9. Chief Medical Officer (CMO) Scotland**

A Rule 9 request was issued on 27 September 2023. The Inquiry has asked CMO Scotland to address the following topics: an overview of the role of CMO Scotland and its role in respect to vaccines; vaccine delivery; new therapeutics and existing medications; public messaging relating to vaccines and learning lessons.

Current status: CMO Scotland provided its draft statement on 15 December 2023 and it is under consideration by the Inquiry.

**10. Chief Medical Officer (CMO) for Northern Ireland and Northern Ireland Department of Health (NIDH)**

A Rule 9 request was issued on 13 September 2023. The Inquiry has the asked the Department to address the following topics: An overview of the role of NIDH; vaccine delivery - eligibility, prioritisation and roll out; public messaging relating to Covid 19 vaccines; barriers to uptake; vaccine dis/misinformation; inequalities; vaccine safety; new therapeutics and existing medications; CMO function within NIDH and learning lessons.

Current status: CMO NI provided its draft statement on 21 December 2023 and it is under consideration by the Inquiry

**11. NHS England**

A Rule 9 letter was issued on 2 October 2023. The Inquiry asked NHS England to address the following topics: Its structure, role, people and processes; key decisions, actions and documents; vaccine delivery in England; data collection and use; vaccine mis/disinformation and public messaging; disparities in vaccines coverage and inequalities; vaccine delivery: liaison and lesson learning across the four nations and beyond; therapeutics: trials and eligibility and lesson learning.

Current status: NHS England is due to provide its draft witness statement by 19 January 2024.

**12. Dr Dame Emily Lawson, NHS England (Senior Responsible Officer - NHS Vaccine Deployment)**

A Rule 9 letter was issued on 3 October 2023. The Inquiry has asked Dr Lawson to address the following topics: An overview of her role generally and specifically in relation to vaccines; vaccine delivery programme and roll-out procedures; barriers to vaccine uptake; public messaging in respect of the vaccines; mis/disinformation and learning lessons.

Current status: Dr Lawson is due to provide her statement by 31 January 2024.

**13. Scottish Health Boards**

A Rule 9 letter was issued on 18 October 2023. The Inquiry asked the Scottish Health Board to address the following topics: An overview of its role, functions and responsibilities; key decisions, actions and documents; development, trials and use of new therapeutics during the pandemic, in addition to the use of existing medications; vaccine delivery and roll-out procedures; public messaging; barriers to vaccine uptake; inequalities and learning lessons.

Current status: Deadline under discussion.

**14. NHS Wales/ Andrew Goodall (Director General Health and Social Services and Chief Executive, NHS Wales)**

A Rule 9 letter was issued on 20 October 2023. The Inquiry has asked NHS Wales to address the following topics: Structure, role, people and processes; key decisions, actions and documents; vaccine delivery in Wales; data collection and use; vaccine mis/disinformation and public messaging; vaccine delivery; liaison and lesson learning across the four nations and beyond; therapeutics: trials and eligibility and lesson learning.

Current status: Andrew Goodall for NHS Wales is due to provide his draft statement by 18 January 2024.

**15. Public Health Wales**

A Rule 9 letter was sent on 25 October 2023. The Inquiry asked Public Health Wales to address the following topics: Structure, role, people and processes, key decisions, actions and documents; development of vaccines; Covid-19 vaccines: eligibility and prioritisation; vaccine delivery in Wales; disparities in vaccine coverage and inequalities; vaccine delivery: liaison and lesson learning across the four nations and beyond; vaccine uptake surveillance, data collection and use; public messaging about the Covid-19 vaccines; vaccine hesitancy; vaccine mis/disinformation; therapeutics: trials and eligibility and lesson learning.

Current status: Public Health Wales is due to provide its draft statement on 19 January 2024.

**16. Public Health Agency Northern Ireland**



A Rule 9 letter was issued on 23 October 2023. The Inquiry asked Public Health Agency NI to address the following topics: structure, role, people and processes, key decisions, actions and documents; overview of role of PHA (NI); Vaccine delivery - eligibility and prioritisation decisions; disparities in vaccine coverage; vaccine uptake surveillance, data collection and use; public messaging in respect of Covid-19 vaccines; vaccine hesitancy; vaccine disinformation and misinformation; vaccine safety; new therapeutics and existing medications; cross-border co-operation and learning lessons.

Current status: Public Health Agency NI is due to provide its draft statement on 31 January 2024.

**17. Department of Science, Innovation & Technology (DSIT) (formerly the Department for Business, Energy and Industrial Strategy (BEIS)).**

A Rule 9 request was issued on 20 July 2023. The Inquiry has asked DSIT to address the following topics: The Vaccine Task Force (VTF) - structure, role, people and processes, key decisions, actions and documents; development, procurement and manufacture of vaccines; vaccine safety; DSIT/BEIS: role and responsibilities; DSIT/BEIS: key decisions, actions and documents; therapeutics and repurposed medications.

Current status: DSIT's draft statement was provided on 3 November 2023. A revised statement was provided on 19 December 2023 and it is under consideration by the Inquiry.

**18. Sir Patrick Vallance (Government Chief Scientific Advisor (GCSA))**

A Rule 9 letter was issued on 6 September 2023. The Inquiry asked Sir Patrick Vallance to address the following topics: His professional background; the role of the GCSA; His role in establishing the Vaccine Task Force (VTF) and the role/ function/ responsibilities of the VTF; the general development, procurement, manufacture and approval of vaccines; vaccine delivery; pre-pandemic preparedness in respect of therapeutics; the development, trials and use of new and existing therapeutics and lessons learning.

Current status: Sir Patrick is due to provide his draft statement by 29 January 2024.

**19. Dame Kate Bingham (former Chair of the Vaccine Task Force (VTF))**

A Rule 9 letter was issued on 29 September 2023. The Inquiry asked Dame Kate Bingham to address the following topics: The VTF's structure, role, people and processes; VTF key documents; development, procurement, manufacture and approval of vaccines; vaccine delivery; public messaging, vaccine safety; independence and impartiality of MHRA; prophylactics and lesson learning.

Current status: Dame Kate Bingham was due to provide her draft statement on 24 November 2023 but the deadline has been extended to 22 December 2023. We are liaising with legal representatives regarding the provision of the statement.

**20. Sir Richard Sykes (former Chair of the Vaccine Task Force (VTF))**

A Rule 9 letter was issued on 29 September 2023. The Inquiry asked Sir Richard Sykes to address the following topics in relation to the VTF: Its structure, role, people and processes; VTF key documents; development, procurement, management and approval of vaccines; vaccine delivery; public messaging; vaccine safety; Independence and impartiality of MHRA; Prophylactics and lessons learned.

Current status: Sir Richard Sykes was due to provide his draft statement on 24 November 2023 but the deadline has been extended to 22 December 2023. We are liaising with legal representatives regarding the provision of the statement.

**21. Professor Sir Peter Horby (RECOVERY trial)**

A Rule 9 letter was issued on 1 September 2023. The Inquiry asked Professor Horby to address the following topics: The RECOVERY trial: roles and responsibilities; genesis, design and set up; oversight, governance, organisational structure and decision-making; working with external organisations and individuals; participant selection; therapeutic selection; conduct of the trial in practice; data analysis, monitoring and management; quality management; safety monitoring; results; impact of RECOVERY and associated trials; transparency and public engagement; lesson learning; NERVTAG: a brief overview of functions, responsibilities and work of NERVTAG AND SAGE FOR Covid 19; other committees, groups and organisations; lesson learning and key decisions, actions and documents.

Current status: Professor Horby was due to provide his statement on 29 November 2023, but the deadline has been extended to 31 January 2024.

**22. Charlotte Taylor (Therapeutics taskforce)**

A Rule 9 letter was issued on 1 August 2023. The Inquiry asked Ms Taylor to address the following topics: The Therapeutic Taskforce's structure, role, people and processes; key decisions, actions and documents; development, trials and use of new therapeutic in addition to use of existing medication and lessons learned.

Current status: Charlotte Taylor provided her draft witness statement on 1 December 2023 and is under consideration by the Inquiry.

**23. Professor Lim (Joint Committee on Vaccination and Immunisation (JCVI))**

A Rule 9 request was issued on 20 July 2023. The Inquiry asked the JCVI to address the following topics: JCVI's structure, role, people and processes; JCVI key decisions and actions and documents; JCVI's involvement in vaccine delivery and uptake; public messaging; unequal uptake; vaccine safety and lesson learning.

Current status: Professor Lim provided his draft statement on 23 November 2023 and it is under consideration by the Inquiry.

**24. Nick Elliott (former Director General of the Vaccine Taskforce (VTF))**

A Rule 9 letter was issued on 19 September 2023. The Inquiry asked Mr Elliot to address the following topics in relation to the VTF: Its structure, role, people and processes; VTF key documents; development, procurement, management and approval of vaccines; vaccine delivery; public messaging; vaccine safety; prophylactics and lessons learned.

Current status: Mr Elliott was due to provide his statement on 14 November 2023, but the deadline has been extended to 15 December 2023. We are liaising with legal representatives regarding the provision of the statement.

**25. Eddie Gray (former Chair of Antivirals Taskforce (ATF))**

A Rule 9 letter was issued on 3 October 2023. The Inquiry asked Mr Gray to address the following topics about the ATF: Its structure, role, people and processes; key decisions, actions and documents; development, trials and use of new therapeutics during the pandemic & use of existing medications and lessons learned.

Current status: Mr Gray was due to provide his draft statement on 28 November 2023, but the deadline has been extended to 31 January 2024.

**26. Commission on Human Medicines (CHM)**

A Rule 9 request was issued on 4 August 2023. The Inquiry has asked the CHM to address the following topics: Its structure, role, people and processes; key decisions, actions and documents; overview of the actions taken by CHM to discharge its statutory functions; the role of CHM; Independence and impartiality of CHM; The regulatory and approval process for Covid-19 vaccines and therapeutics; Covid-19 vaccine safety issues; prophylactic treatments; lesson learning.

Current status: The Commission on Human Medicines provided its draft statement on 11 December 2023 and it is under consideration by the Inquiry.

**27. The National Institute for Health and Care Excellence (NICE)**

A Rule 9 request was issued on 26 July 2023. The Inquiry asked NICE to address the following topics: Its structure, role, people and processes; NICE key decisions, actions and documents; guidance produced in response to Covid-19 pandemic; Covid-19 Rapid Guidelines; RAPID C-19; public communication; barriers to vaccination uptake and lesson learning.

Current status: NICE provided two draft statements on 20 September 2023, which are under consideration by the Inquiry.

**28. Medicines and Healthcare Products Regulatory Agency (MHRA)**

A Rule 9 request was issued on 24 July 2023. The Inquiry asked the MHRA to address the following topics: Its structure, role, people and processes; key decisions, actions and documents; the regulatory and approval process for Covid-19 vaccines; post-approval monitoring of Covid-19 vaccines; Covid-19 vaccine safety issues; independence and impartiality of MHRA; therapeutics and lesson learning.

Current status: MHRA is providing its draft statement in phases, with the final complete draft statement due on 12 January 2024.

**29. UK Health Security Agency (UKHSA)**

A Rule 9 letter request was issued on 11 July 2023 and a section 21 Notice was issued on 17 October 2023. The Inquiry has asked the UKHSA to provide a witness statement addressing both UKHSA/ Public Health England (PHE) issues and Vaccine Task Force (VTF) issues. In relation to UKHSA/ PHE, the Inquiry has sought information about: Its structure, role, people and processes; key decisions, actions and documents; vaccine delivery; public messaging; unequal update; vaccine safety; therapeutics and lesson learning. In relation to VTF issues, the Inquiry has sought information about: Its structure, role, people and processes; VTF key decisions, actions and documents; development, procurement, manufacture and approval of vaccines; vaccine delivery; vaccine safety and lesson learning.

Current status: UKHSA's witness statement addressing VTF issues is due on 16 February 2024. UKHSA's witness statement addressing UKHSA/PHE issues is due on 26 February 2024.

**30. Professor Dame Sarah Gilbert (Professor of Vaccinology, University of Oxford)**

A Rule 9 letter was issued on 3 October 2023. The Inquiry asked Professor Dame Sarah Gilbert to address the following topics: Her role at the Oxford University and the structure, role, people & process at Oxford University in relation to the development of the Oxford-AstraZeneca vaccine; The UK's preparedness to develop vaccines including lessons learned; the Oxford-AstraZeneca vaccine; innovations introduced and lessons learned; vaccine roll out; safety; and vaccine mis/disinformation.

Current status: Professor Dame Sarah Gilbert provided her draft witness statement on 28 November 2023 and it is under consideration by the Inquiry.

**31. The Counter Disinformation Unit (CDU), Department for Culture, Media and Sport (DCMS)**

A Rule 9 letter was issued on 21 August 2023. The Inquiry asked the CDU to address the following topics: Its structure, role, people and processes; the establishment of the CDU and questions addressing matters such as key individuals and regulation; the relationship between the Rapid Response Unit and CDU; Mis/disinformation on Covid vaccines and public messaging.

Current status: The CDU DCMS provided its draft statement on 21 November 2023 and it is under consideration by the Inquiry.

**32. NHS Business Service Authority (NHSBSA)**

A Rule 9 request was issued on 26 June 2023. The Inquiry asked the NHSBSA to address the following topics: The role of the NHSBSA; background to the VDPS; The

VDPS and Covid-19 vaccines; eligibility and payment limits; the application process; data on the operation of the VDPS; reforms and lesson learning.

Current status: The NHSBSA provided a revised draft statement on 20 October 2023 and it is under consideration by the Inquiry.

**33. Department for Work & Pensions (DWP)**

A Rule 9 request was issued on 26 June 2023. The Inquiry asked the DWP to address the following topics: background to the Vaccine Damage Payment Scheme (VDPS) and its operation; the VDPS and Covid-19 vaccines; eligibility and time limits; the application process; data on the operation of the VDPS; reforms and lesson learning.

Current status: The DWP provided its draft statement and exhibits on 31 July 2023 and provided its final draft statement on 4 January 2024.

**34. AstraZeneca UK Limited**

A Rule 9 letter was issued on 23 August 2023. The Inquiry asked AstraZeneca UK Ltd to address the following topics: Its structure, role, people and processes; key decisions, actions and documents; vaccine preparedness; development of the Oxford/ Astrazeneca vaccine; the approval process; vaccine delivery and prioritisation; vaccine safety; therapeutics; The UK Vaccine Damage Payment Scheme (VDPS) and lessons learned and preparing for a future pandemic.

Current status: AstraZeneca UK Ltd provided two of three draft statements on 15 December 2023 and they are under consideration by the Inquiry.

**35. Pfizer Limited**

A Rule 9 letter was issued on 18 October 2023. The Inquiry asked Pfizer Ltd to address the following topics: Its structure, role, people and processes; key decisions, actions and documents; vaccine preparedness; development of covid-19 vaccines; the approval process; vaccine delivery and prioritisation; vaccine safety; therapeutics; The UK Vaccine Damage Payment Scheme (VDPS) and lessons learned and preparing for the future.

Current status: Pfizer Ltd's witness statement was due on 13 December 2023, but the deadline has been extended to 19 January 2024.

**36. Moderna Biotech UK Limited**

A Rule 9 letter was issued on 18 September 2023. The Inquiry asked Moderna Biotech Uk Ltd to address the following topics: Its structure, role, people and processes; key decisions, actions and documents; vaccine preparedness; development of Covid 19 vaccine; the approval process; vaccine delivery and prioritisation; vaccine safety; therapeutics; the UK Vaccine Damage Payment Scheme (VDPS) and lessons learned and preparing for a future pandemic.

Current status: Moderna Biotech UK Limited provided its draft statement on 8 December 2023 and it is under consideration by the Inquiry.

**37. BioNTech UK Limited**

A Rule 9 letter was issued on 17 October 2023. The Inquiry has asked BioNTech Ltd to address the following topics: Its structure, role, people and processes; key decisions, actions and documents; vaccine preparedness; the development of Covid-19 vaccines, the approvals process; vaccine delivery and prioritisation; vaccine safety, therapeutics; The UK Vaccine Damage Payment Scheme (VDPS) and lessons learned and preparing for a future pandemic.

Current status: The draft statement was due on 12 December 2023, but the deadline has been extended to 19 January 2024.

**38. Janssen-Cilag Limited**

A Rule 9 letter was issued on 19 September 2023. The Inquiry asked Janssen-Cilag Ltd to address the following topics: Its structure, role, people and processes; key decisions, actions and documents; vaccine preparedness; development of Covid 19 vaccine; the approval process; vaccine delivery and prioritisation; vaccine safety; therapeutics; the UK Vaccine Damage payment Scheme (VDPS) and lessons learned and preparing for a future pandemic.

Current status: Janssen-Cilag Limited provided its draft statement on 17 November 2023 and this is under consideration by the Inquiry.

**39. GlaxoSmithKline (GSK) Limited**

A Rule 9 letter was sent on 10 October 2023. The Inquiry asked GSK Ltd to address the following topics: Its structures, role, people and processes; key decisions, actions and documents; vaccine preparedness; development of the Covid-19 vaccines; the approvals process; vaccine delivery and prioritisation; vaccine safety; therapeutics; The UK Vaccine Damage Payment Scheme (VDPS) and lessons learned and preparing for a future pandemic.

Current status: GlaxoSmithKline Ltd provided its draft statements on 6 December 2023 and they are under consideration by the Inquiry.

**40. Novavax UK Limited**

A Rule 9 letter was issued on 5 September 2023. The Inquiry asked Novavax UK Ltd to address the following topics: Its structure, role, people and processes; key decisions, actions and documents; vaccine preparedness; development of Covid 19 vaccine; the approval process; vaccine delivery and prioritisation; vaccine safety; therapeutics; the UK Vaccine Damage Payment Scheme (VDPS) and lessons learned and preparing for a future pandemic.

Current status: Novavax UK Limited was due to provide its draft statement by 31 October 2023, but the deadline has been extended to 26 January 2024.

**41. Sanofi UK (Aventis Pharma Limited and Opella Healthcare UK Limited)**

A Rule 9 letter was issued on 18 October 2023. The Inquiry asked Sanofi UK to address the following topics: Its structure, role and processes, key decisions, actions and documents, vaccine preparedness; development of Covid-19 vaccine; the approval process; vaccination delivery and prioritisation; vaccine safety; therapeutics and lessons learned and preparing for a future pandemic.

Current status: Sanofi UK was due to provide its draft statement by 13 December 2023, but the deadline has been extended to 15 January 2024.

**42. Valneva UK Limited**

A Rule 9 letter was issued on 18 September 2023. The Inquiry asked Valneva UK Ltd to address the following topics: Its structure, role, people and processes; key decisions, actions and documents; vaccine preparedness; development of Covid 19 vaccine; approval process; vaccine delivery and prioritisation; vaccine safety; therapeutics; UK VDPS; lessons learned and preparing for a future pandemic.

Current status: Valneva UK Limited provided its draft statement on 7 December 2023 and it is under consideration by the Inquiry.

**43. Covid-19 Bereaved Families for Justice UK (CBFFJ)**

A Rule 9 letter was issued on 29 August 2023. The Inquiry asked CBFFJ to address the following topics: A description of the organisation and overview of its membership; an overview of the organisation's concerns in relation to the provisional outline of scope for Module 4; A summary of any formal engagement with government departments, the devolved nations or other public bodies; a summary of any reports the CBFFJ has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: CBFFJ provided its draft statement on 13 November 2023. It provided an updated statement on 4 December 2023 and it is under consideration by the Inquiry.

**44. NI Covid-19 Bereaved Families for Justice (NI CBFJ)**

A Rule 9 letter was issued on 29 August 2023. The Inquiry asked NI CBFJ to address the following topics: A description of the organisation and an overview of its membership; an overview of the organisation's concerns in relation to the provisional outline of scope for Module 4; a summary of any engagement with UK Government departments, the NI Executive or other public bodies relating to the provisional scope for Module 4; a summary of any reports the NI CBFJ has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: NI CBFJ was due to provide its draft statement by 24 October 2023, but the deadline has been extended to 19 January 2024.

**45. Scottish Covid Bereaved (SCB)**

A Rule 9 letter was issued on 29 August 2023. The Inquiry asked the SCB to address the following topics: A description of the organisation and an overview of its membership; an overview of organisation's concerns in relation to the provisional scope for Module 4; a summary of any engagement with UK Government departments, the devolved administrations or other public bodies relating to the provisional scope for Module 4; a summary of any reports the SCB has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: The SCB provided a draft statement on 20 October 2023 and this is under consideration by the Inquiry.

**46. Covid-19 Bereaved Families For Justice Cymru Group (CBFJ Cymru)**

A Rule 9 letter was issued on 29 August 2023. The Inquiry asked the CBFJ Cymru to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any engagement with UK Government departments, the devolved administrations or other public bodies relating to the matters set out in the provisional scope for Module 4; a summary of any reports the CBFJ Cymru has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: CBFJ Cymru provided its statement on 20 December 2023 and it is under consideration by the Inquiry.

**47. Clinically Vulnerable Families (CVF)**

A Rule 9 letter was issued on 31 August 2023. The Inquiry asked CVF to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any formal engagement with government departments, the devolved nations or other public bodies relating to the matters set out in the provisional scope for Module 4; a summary of any reports the CVF has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: CVF is due to provide its draft statement by 30 November 2023, but the deadline has been extended to 22 December 2023. We are in discussions with CVF about the arrangements for the provision of its statement.

**48. Vaccine Injured and Bereaved UK (VIBUK)**



A Rule 9 letter was issued on 31 August 2023. The Inquiry asked VIBUK to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any formal engagement with government departments, the devolved nations or other public bodies relating to the matters set out in the provisional scope for Module 4; a summary of any reports the VIBUK has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: VIBUK provided its draft witness statement on 27 October 2023 and this is under consideration by the Inquiry.

**49. UK CV Family**

A Rule 9 letter was issued on 31 August 2023. The Inquiry asked UK CV Family to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any formal engagement with government departments, the devolved nations or other public bodies relating to the matters set out in the provisional scope for Module 4; a summary of any reports the UK CV Family has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: UK CV Family provided its draft statement on 1 December 2023 and this is under consideration by the Inquiry.

**50. Scottish Vaccine Injury Group**

A Rule 9 letter was issued on 31 August 2023. The Inquiry asked the Scottish Vaccine Injury Group to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any formal engagement with government departments, the devolved nations or other public bodies relating to the matters set out in the provisional scope for Module 4; a summary of any reports the Scottish Vaccine Injury Group has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: Scottish Vaccine Injury Group provided a draft witness statement on 26 October 2023 and this is under consideration by the Inquiry.

**51. Disability Rights UK (DR UK)**

A Rule 9 letter was issued on 30 August 2023. The Inquiry asked DR UK to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any formal engagement with government departments, the devolved nations or other public bodies relating to the matters set out in the provisional

scope for Module 4; a summary of any reports DR UK has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: DR UK was due to provide its draft statement by 24 November 2023, but the deadline has been extended to 26 January 2024.

**52. Disability Action Northern Ireland (DANI)**

A Rule 9 letter was issued on 30 August 2023. The Inquiry asked DANI to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any formal engagement with government departments, the devolved nations or other public bodies relating to the matters set out in the provisional scope for Module 4; a summary of any reports DANI has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: DANI was due to provide its draft statement by 24 November 2023, but the deadline has been extended to 26 January 2024.

**53. Disability Wales (DW)**

A Rule 9 letter was issued on 30 August 2023. The Inquiry asked DW to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any formal engagement with government departments, the devolved nations or other public bodies relating to the matters set out in the provisional scope for Module 4; a summary of any reports DW has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: DW was due to provide its draft statement by 24 November 2023, but the deadline has been extended to 26 January 2024.

**54. Inclusion Scotland (IS)**

A Rule 9 letter was issued on 30 August 2023. The Inquiry asked IS to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any formal engagement with government departments, the devolved nations or other public bodies relating to the matters set out in the provisional scope for Module 4; a summary of any reports IS has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: IS was due to provide its draft statement by 24 November 2023, but the deadline has been extended to 26 January 2024.

**55. Federation of Ethnic Minority Healthcare Organisations (FEMHO)**

A Rule 9 letter was issued on 31 August 2023. The Inquiry asked FEMHO to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any formal engagement with government departments, the devolved nations or other public bodies relating to the matters set out in the provisional scope for Module 4; a summary of any reports FEMHO has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: FEMHO was due to provide its draft statement by 26 October 2023, but the deadline has been extended to 15 February 2024.

**56. Migrant Primary Care Access Group (MPCAG)**

A Rule 9 letter was issued on 31 August 2023. The Inquiry asked MPCAG to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any formal engagement with government departments, the devolved nations or other public bodies relating to the matters set out in the provisional scope for Module 4; a summary of any reports MPCAG has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: MPCAG provided its draft statement on 21 November 2023 and this is under consideration by the Inquiry.

**57. The Traveller Movement**

A Rule 9 letter was issued on 31 August 2023. The Inquiry asked The Traveller Movement to address the following topics: a description of the organisation and an overview of its membership; an overview of the organisation's concerns as they relate to the provisional scope for Module 4; a summary of any formal engagement with government departments, the devolved nations or other public bodies relating to the matters set out in the provisional scope for Module 4; a summary of any reports The Traveller Movement has contributed to or published and any evidence given regarding the matters set out in the provisional scope for Module 4 and lessons learned/recommendations.

Current status: The Traveller Movement provided its draft statement on 23 November 2023 and this is under consideration by the Inquiry.

**58. The Perseus Group**

A Rule 9 letter was issued on 24 October 2023. The Inquiry asked The Perseus Group to address the following topics: a brief description of the organisation, including its history, purpose and aims; a general overview of its membership and the people it

represents; an overview of the concerns which the Perseus Group has identified in relation to the matters set out in the Provisional Outline for Scope of Module 4; a summary of any formal engagement with UK government departments, the devolved administrations or other public bodies relating to the matters set out in the Provisional Outline for Scope of Module 4; a summary of any reports it has published or contributed to, and/or evidence it has given (for example to Parliamentary Select Committees) regarding the matters set out in the Provisional Outline for Scope of Module 4 and lesson learning.

Current status: Perseus Group provided its draft statement on 14 December 2023 and this is under consideration by the Inquiry.

**59. The Home Office**

A Rule 9 letter was issued on 2 November 2023. The Inquiry asked the Home Office to address the following topics: The steps taken by the Home Office to engage with barriers to access to vaccines and therapeutics specific to the migrant community; adaption of roll-out practicalities to the needs of the migrant community; The Home Office's broader role in development of vaccines and therapeutics.

Current status: The Home Office is due to provide its draft statement on 19 January 2024.

**60. Nuffield Council on Bioethics**

A Rule 9 letter was sent on 2 November 2023. The Inquiry asked Nuffield Council on Bioethics to address the following topics: The ethical issues in the context of vaccine delivery; the consideration of ethical issues in the context of vaccine delivery by the UK Government, the devolved administrations or other relevant bodies and organisations; engagement with the UK Government, the devolved administrations or other relevant bodies and organisations on ethical issues in the context of vaccine delivery.

Current status: Nuffield Council on Bioethics is due to provide its draft statement by 26 January 2024.

**61. Professor Sir John Bell**

A Rule 9 letter was sent to Professor Sir John Bell on 16 November 2023. The Inquiry asked Professor Bell to address the following topics: His role in developing Oxford-AstraZeneca vaccine; the development of a commercial relationship with AstraZeneca; safety issues in relation to Oxford-AstraZeneca vaccine specifically and the function of Life Sciences Champion, including how lessons learned during the pandemic in relation to vaccines and therapeutics are being factored into the current work of the UK Government's Life Sciences Vision.

Current status: Professor Bell is due to provide his draft statement by 31 January 2024.

**62. Professor Sir Jonathan Van-Tam (former Deputy Chief Medical Officer)**

A Rule 9 letter was sent to Professor Van-Tam on 17 November 2023. The Inquiry asked Professor Van-Tam to address the following topics: development, procurement, manufacture and approval of the Covid-19 vaccines; prophylactics; eligibility and prioritisation for Covid-19 vaccines; roll-out of the Covid-19 vaccines and coverage; public messaging on the Covid-19 vaccines; vaccine hesitancy; Vaccine as a Condition of Deployment (“VCOD”); disinformation and misinformation in relation to the Covid-19 vaccines; inequalities in access to and uptake of the vaccines; safety of the Covid-19 vaccines; development of new or repurposed therapeutics; and his role in SAGE.

Current status: Professor Van-Tam is due to provide his draft witness statement by 16 February 2024.

**63. Professor Sir Andrew Pollard**

A Rule 9 letter was sent to Professor Sir Andrew Pollard on 17 November 2023. The Inquiry asked Professor Pollard to address the following topics: The development of the Oxford-AstraZeneca vaccine; the roll-out of the Oxford-AstraZeneca vaccine including decisions on eligibility; safety of the Oxford-AstraZeneca vaccine including known risks such as blood clots and vaccine disinformation / misinformation

Current status: Professor Sir Andrew Pollard is due to provide his draft witness statement by 2 February 2024.

**64. Association of Directors of Adult Social Services (ADASS)**

A Rule 9 letter was sent to the ADASS on 14 November 2023. The Inquiry asked ADASS to address the following topics: the roll-out procedures for the Covid-19 vaccines; public messaging on the Covid-19 vaccine roll-out; vaccine hesitancy in relation to the Covid-19 vaccines; dis/misinformation about the Covid-19 vaccines; and inequalities in relation to access to and uptake of the Covid-19 vaccines.

Current status: ADASS is due to provide its draft statement to the Inquiry on 23 January 2024.

**65. The Foreign, Commonwealth and Development Office (FCDO)**

A Rule 9 letter was sent on 9 November 2023. The Inquiry asked the FCDO to address the following topics: Its role in the development, manufacture, procurement and approval of Covid-19 vaccines and therapeutics; the UK’s international Covid-19 vaccine and therapeutic strategy; The interplay between international and domestic matters in relation to the Covid-19 vaccines and therapeutics and Lessons learned.

Current status: FCDO is due to provide its draft statement by 27 February 2024.

**66. Welsh Government**

A Rule 9 letter was sent on 14 November 2023. The Inquiry asked the Welsh Government to address the following topics: The Welsh Government’s role in the

development, manufacture and procurement of the Covid-19 vaccines; development of prophylactics; vaccine delivery including decisions on eligibility and prioritisation and rollout practicalities in Wales; disparities in uptake of vaccine in Wales including steps taken to address these; public messaging in Wales on Covid-19 vaccines; vaccine hesitancy in Wales; the Vaccine Damage Payment Scheme; the development of new and repurposed therapeutics for the treatment of Covid-19 in Wales; Lessons learned by the Welsh Government in relation to Module 4 matters.

Current status: The Welsh Government provided its draft statement on 15 December 2023 and this is under consideration by the Inquiry.

**67. Health Advisory and Recovery Team (HART)**

A Rule 9 letter was issued on 7 November 2023. The Inquiry asked HART to address the following topics: an overview of the concerns which HART has identified in relation to Provisional Outline of Scope for Module 4, including vaccine safety, post marketing surveillance and public messaging; engagement with other UK organisations; summary of reports published; and lessons learned.

Current status: HART is due to provide its draft statement on 16 January 2024.

**68. The UK Medical Freedom Alliance (UKMFA)**

A Rule 9 letter was issued on 8 November 2023. The Inquiry asked UKMFA to address the following topics: an overview of the concerns which UKMFA has identified in relation to Provisional Outline of Scope for Module 4, including the development and approval of vaccines, vaccine delivery and vaccine safety issues; engagement with other UK organisations; summary of reports published; and lessons learned.

Current status: UKMFA is due to provide its draft statement on 19 January 2024.

**69. The Children's Covid Vaccines Advisory Council (CCVAC)**

A Rule 9 letter was issued on 9 November 2023. The Inquiry asked the CCVAC to address the following topics: an overview of the concerns which CCVAC has identified in relation to Provisional Outline of Scope for Module 4, including the development and approval of vaccines, the JCVI recommendations on eligibility and decisions taken by policymakers concerning the vaccination of children and vaccine safety issues; engagement with other UK organisations; summary of reports published; and lessons learned.

Current status: CCVAC is due to provide its draft statement on 18 January 2024.

**70. Forgotten Lives UK**

A Rule 9 letter was issued on 9 November 2023. The Inquiry asked Forgotten Lives UK to address the following topics: an overview of the concerns which Forgotten

Lives UK has identified in relation to Provisional Outline of Scope for Module 4, including barriers to uptake of the Covid-19 vaccines for immunocompromised and immunosuppressed people and decision-making around non-vaccine prophylactics, including Evusheld; engagement with other UK organisations; summary of reports published; and lessons learned.

Current status: Forgotten Lives UK is due to provide its draft statement on 31 January 2024.

**71. St John Ambulance**

A Rule 9 letter was issued on 3 November 2023. The Inquiry asked St John Ambulance to address the following topics: overview of its role in relation to Covid 19 vaccines; vaccine delivery programmes and roll out procedures, including inequalities; barriers to vaccine uptake; public messaging; experiences of mis/disinformation in relation to the Covid-19 vaccines; and lessons learned.

Current status: St John Ambulance is due to provide its draft statement on 2 February 2024.

**72. The Department for Levelling Up, Housing and Communities (DLUHC)**

A Rule 9 letter was sent on 9 November 2023. The Inquiry asked DLUHC to address the following topics: overview of its role in relation to Covid-19 vaccines; Covid-19 vaccine delivery and roll-out procedures, including inequalities; equality of vaccine coverage; vaccination as a condition of deployment; public messaging in relation to the Covid-19 vaccines; vaccine hesitancy; dis/misinformation; and lessons learned.

Current status: DLUHC is due to provide its draft statement by 2 February 2024.

**73. Professor Sir Martin Landray (Joint Chief Investigator for RECOVERY trial)**

A Rule 9 letter was sent to Professor Sir Martin Landray on 2 November 2023. The Inquiry asked Professor Landray to address the following topics: overview of his role in relation to the RECOVERY trial and lessons learned.

Current status: Professor Landray is due to provide his draft statement by 23 February 2024.

**74. The British Medical Association (BMA)**

A Rule 9 letter was sent to the BMA on 10 November 2023. The Inquiry asked the BMA to address the following topics: Covid-19 vaccine delivery programme and roll-out procedures; vaccination as a condition of deployment; barriers to vaccine uptake, including inequalities; public messaging in relation to the Covid-19 vaccines; experiences of dis/misinformation in relation to the Covid-19 vaccines; and lessons learned.

Current status: The BMA is due to provide its draft statement by 29 February 2024.

**75. The National Institute for Health Research (NIHR)**

A Rule 9 letter was sent to NIHR on 20 November 2023. The Inquiry asked the NIHR to address the following topics: UK preparedness; NIHR's response to Covid-19; development of vaccines; procurement, manufacture and approval of Covid-19 vaccines; development, trials and use of new therapeutics during the pandemic, in addition to the use of existing medications; RAPID C-19; vaccine hesitancy; public engagement; impact of NIHR's funding and research work; and lessons learned.

Current status: Deadline under discussion.

**76. The National Pharmacy Association (NPA)**

A Rule 9 letter was sent to the NPA on 10 November 2023. The Inquiry asked the NPA to address the following topics: overview of the NPA's role in respect of Covid-19 vaccines; Covid-19 vaccine delivery programme and roll-out procedures; funding; barriers to vaccine uptake, including inequalities; public messaging; dis/misinformation in relation to the Covid-19 vaccines; and lessons learned.

Current status: The NPA is due to provide its draft statement by 23 February 2024.

**77. Mr Vaughan Gething (former Minister for Health and Social Services in the Welsh Government)**

A Rule 9 letter was sent to Mr Vaughan Gething on 14 November 2023. The Inquiry asked Mr Gething to address the following topics: His role in relation to the development, manufacture and procurement of the Covid-19 vaccines; vaccine delivery including decisions on eligibility and prioritisation, roll-out procedures and steps taken to address unequal coverage; his role in public messaging in Wales on Covid-19 vaccines; his understanding of vaccine hesitancy in Wales; the development of new and repurposed therapeutics for the treatment of Covid-19 in Wales and lessons learned.

Current status: Mr Gething is due to provide his draft witness statement on 15 January 2024.

**78. NHS Wales (Dr Andrew Goodall)**

A Rule 9 letter was sent to Dr Andrew Goodall on 20 October 2023. The Inquiry asked Dr Goodall to address the following topics: vaccine delivery in Wales; data collection and use; vaccine misinformation / disinformation and public messaging; disparities in vaccine coverage and inequalities; liaison and lesson learning across the four nations; therapeutic trials and eligibility; and lesson learning.

Current status: Dr Goodall is due to provide his draft witness statement on 18 January 2024.

**79. Professor Anthony Gordon (Chief Investigator of REMAP-CAP)**



A Rule 9 request was sent to Professor Anthony Gordon on 22 November 2023. The Inquiry asked Professor Gordon to address the following topics: role and responsibilities in relation to REMAP-CAP, genesis and design of REMAP-CAP, oversight, governance, organisational structure and decision-making in relation to REMAP-CAP; conduct of the trial in practice, results and impact; transparency and public engagement; and lessons learned.

Current status: Professor Gordon is due to provide his statement to the Inquiry by 31 January 2024.

**80. Baroness Arlene Foster of Aghadrumsee DBE (former First Minister of Northern Ireland)**

A Rule 9 letter was sent to Baroness Foster on 23 November 2023. The Inquiry asked Baroness Foster to address the following topics: liaison with the devolved nations and UK Government in relation to development, procurement, manufacture and approval of vaccines; eligibility and prioritisation for Covid-19 vaccines in Northern Ireland; roll-out strategy for Covid-19 vaccines in Northern Ireland; public messaging in relation to Covid-19 vaccines in Northern Ireland; therapeutics; and inequalities.

Current status: Deadline for under discussion.

**81. Professor Chris Butler (Co-Chief Investigator of the PRINCIPLE and PANORAMIC trials)**

A Rule 9 letter was sent to Professor Chris Butler on 27 November 2023. The Inquiry asked Professor Butler to address the following topics in relation to the PRINCIPLE and PANORAMIC trials: genesis, design and set up; oversight, governance, organisational structure and decision-making; working with external organisations and individuals; participant and therapeutic selection; conduct of the trial in practice; monitoring and management; results and impact; and lessons learned.

Current status: Professor Butler is due to provide his draft statement by 14 February 2024.

**82. Sarah Moore (Partner at Hausfield law firm)**

A Rule 9 letter was sent to Sarah Moore on 28 November 2023. The Inquiry asked Ms Moore to address the following topics: Her experience of the VDPS in the context of Covid-19, including the application process, eligibility criteria, payment levels and impact of payment on benefits and entitlements; and suggestions for reform.

Current status: Ms Moore is due to provide her draft statement by 19 January 2024.

**83. Public Health Scotland**

A Rule 9 letter was sent to Public Health Scotland on 28 November 2023. The Inquiry asked Public Health Scotland to address the following topics: Covid-19 vaccines eligibility and prioritisation; Covid-19 vaccination programme; disparities in

vaccine coverage, vaccine hesitancy and inequalities; vaccine hesitancy; public messaging about Covid-19 vaccines; vaccine surveillance, data collection and use; development, trials and availability for use of new therapeutics during the pandemic, in addition to the use of existing medications; and lessons learned.

Current status: Public Health Scotland is due to provide its draft statement by 15 March 2024.

**84. Paul Givan (former First Minister of Northern Ireland)**

A Rule 9 letter was sent to Paul Givan on 28 November 2023. The Inquiry asked Paul Givan to address the following topics: liaison with the devolved nations and UK Government in relation to development, procurement, manufacture and approval of vaccines; eligibility and prioritisation for Covid-19 vaccines in Northern Ireland; roll-out strategy for Covid-19 vaccines in Northern Ireland; public messaging in relation to Covid-19 vaccines in Northern Ireland; therapeutics; and inequalities.

Current status: Deadline under discussion.

**85. NHS National Services Scotland (NHS NSS)**

A Rule 9 letter was sent to NHS NSS on 29 November 2023. The Inquiry asked NHS NSS to address the following topics: an overview of NHS NSS; resources and levels of funding for NHS NSS; Audit Scotland Annual Audit Reports; development, trials and use of new therapeutics during the pandemic, in addition to the use of existing medications; Covid-19 vaccine delivery; public messaging; barriers to Covid-19 vaccine uptake; inequalities; and lessons learned.

Current status: NHS NSS is due to provide its draft statement by 4 March 2024.

**86. Faculty of Pharmaceutical Medicine**

A Rule 9 letter was sent to the Faculty of Pharmaceutical Medicine (FPM) on 7 December 2023. The Inquiry asked the FPM to address the following topics: overview of role and membership; summary of any surveys, training, advice carried out by members; views on UK's preparedness and resilience regarding rapid development of vaccine & any lessons learned; FPM's role in relation to Covid 19 vaccines, therapeutics public engagement; lesson learning.

Current status: FPM is due to provide its draft statement by 9 February 2024.

**87. UKRI**

A Rule 9 letter was sent to UKRI on 8 December 2023. The Inquiry asked UKRI to address the following topics: UKRI's structure, role, people and processes; UKRI's response to Covid 19; role and responsibility relating to development of vaccines; overview of UK-CTAP's role and activities in relation to COVID-19 therapeutics; vaccine hesitancy and public engagement; lesson learning.

Current status: UKRI is due to provide its draft statement by 26 February 2024.

**88. Michelle O’Neill (former deputy First Minister of Northern Ireland)**

A draft Rule 9 letter was sent to Michelle O’Neill on 1 December 2023. The Inquiry asked Ms O’Neill to address the following topics: key decisions, actions and documents; development, procurement, manufacture and approval of vaccines; eligibility, prioritisation and roll out; public messaging, therapeutics and inequalities.

Current status: Deadline under discussion.

**89. Royal College of Nursing**

A Rule 9 letter was sent to the Royal College of Nursing (RCN) on 4 December 2023. The Inquiry asked the RCN to address the following topics: overview of the RCN’s role in relation to vaccines and vaccinations; Covid 19 vaccination programme and roll out procedures; vaccination as a condition of deployment; barriers to vaccine uptake; public messaging; mis/disinformation; patient records; inequalities; lesson learning.

Current status: Deadline under discussion.

**90. Madelaine McTernan (former Director General of the UK’s Vaccine Taskforce)**

A Rule 9 letter was sent to Madelaine McTernan on 7 December 2023. The Inquiry asked that Ms McTernan address the following topics: overview of her appointment and role within the Vaccine Taskforce; development, procurement, manufacture and approval of vaccines; vaccine delivery in England, Wales, Scotland and Northern Ireland; public messaging; vaccine safety issues; independence and impartiality of MHRA; prophylactics and lesson learning.

Current status: Deadline under discussion

**91. Professor Duncan Fairgrieve**

A Rule 9 letter was sent to Professor Fairgrieve on 7 December 2023. The Inquiry asked Professor Fairgrieve to address the following topics: overview of background and experience; Financial support for individuals who have suffered damage following vaccinations; The VDPS and Covid-19 vaccines; approaches taken by other jurisdictions to similar schemes; suggested reforms to similar schemes or bespoke Covid 19 schemes.

Current status: Professor Fairgrieve is due to provide his draft statement by 9 February 2024.

**92. Sir Christopher Edwards**

A Rule 9 letter was sent to Sir Christopher on 4 December 2023. The Inquiry asked Sir Christopher to address the following topics: overview of background and

experience; an explanation of Sir Christopher’s work relating to development of Covid 19 therapeutics; lessons learned.

Current status: Sir Christopher provided his draft statement on 9 December 2023 and it is under consideration by the Inquiry.

**93. Rt Hon Sir Alok Sharma (Former Secretary of State for Business, Energy and Industrial Strategy (“BEIS”))**

A Rule 9 letter was sent to Sir Alok on 6 December 2023. The Inquiry asked Sir Alok to address the following topics: overview of role, function and responsibilities; role in relation to development, procurement, manufacture and approval of vaccines; views relating to vaccine safety and public messaging; New and repurposed therapeutics; lesson learning.

Current status: Deadline under discussion.

**94. Clive Dix (former Deputy Chair of the UK’s Vaccine Taskforce)**

A Rule 9 letter was sent to Clive Dix on 5 December 2023. The Inquiry asked Mr Dix to address the following topics: in relation to VTF: structure, role, people and processes; key documents; development, procurement, manufacture and approval of vaccines; vaccine delivery in England, Wales, Scotland and Northern Ireland; public message; vaccines safety issues; independence and impartiality of MHRA; prophylactics; lesson learning.

Current status: Deadline under discussion.

**95. Sir Jeremy Farrar (member of the Expert Advisory Board of the UK Vaccines Taskforce, involvement in the Therapeutics Taskforce and member of the Scientific Advisory Group for Emergencies (“SAGE”))**

A Rule 9 letter was sent to Sir Jeremy on 5 December 2023. The Inquiry asked Sir Jeremy to address the following topics: Re: Development of vaccines and prophylactics; role and responsibilities; Re: Therapeutics: role in relation to the Therapeutics Taskforce & lessons learned; observations relating to SAGE and any other matters pertaining to Module 4.

Current status: Sir Jeremy is due to provide his draft statement by 23 February 2024.